Immune thrombocytopenia (ITP) trials in China

In China 67 Also abroad 118

67 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia
Where
Jinan
Age
18 years and over
People
84
Run by
Shanghai Escugen Biotechnology Co., Ltd
See details and how to joinNCT06853444
Early phase 1Taking people
An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia
Where
Changzhou
Age
18 years to 65 years
People
9
Run by
Changzhou No.2 People's Hospital
See details and how to joinNCT06337474
Phase 2/3Not yet taking people in China
The Study of Different Cycles of High-dose Dexamethasone in the Treatment of ITP
Where
Jinan
Age
18 years and over
People
118
Run by
Shandong University
See details and how to joinNCT06913374
Phase 2Taking people
An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia
Where
Tianjin
Age
18 years and over
People
20
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06799611
Phase 2Taking people
A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP
Where
Tianjin
Age
60 years and over
People
80
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06838949
No phaseNot yet taking people in China
Validation of the EQ-5D-Y-3L and EQ-5D-Y-5L for Paediatric Patients in China
Where
Guiyang
Age
5 years to 16 years
People
360
Run by
RenJi Hospital
See details and how to joinNCT06873672
Phase 2Taking people
Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies
Where
Tianjin
Age
18 years and over
People
52
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT04993885
Phase 2Taking people
A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia
Where
Tianjin
Age
18 years and over
People
30
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT05214391
Phase 2Taking people
A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)
Where
Tianjin
Age
12 years to 18 years
People
60
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06094881
Phase 2Taking people
Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia
Where
Tianjin
Age
6 years to 18 years
People
60
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06281327
Phase 1Taking people
BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases
Where
Chengdu
Age
18 years to 60 years
People
20
Run by
iCell Gene Therapeutics
See details and how to joinNCT06787989
No phaseTaking people
Longitudinal Cohort of Thrombosis and Hemostasis Diseases
Where
Beijing, Chongqing, Zhengzhou
People
3,000
Run by
Peking University People's Hospital
See details and how to joinNCT06727669
Phase 1/2Taking people
Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)
Where
Kunming
Age
8 years to 75 years
People
10
Run by
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
See details and how to joinNCT06352281
No phaseTaking people
The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP
Where
Shanghai
Age
15 years to 99 years
People
126 worldwide
Run by
Yunfeng Cheng
See details and how to joinNCT06479291
No phaseTaking people
The Efficacy and Safety of HCQ Plus Pred in ANA Positive ITP
Where
Shanghai
Age
15 years to 99 years
People
129 worldwide
Run by
Yunfeng Cheng
See details and how to joinNCT06479304
No phaseTaking people
The Efficacy and Safety of HCQ Plus DEX in ANA Positive ITP
Where
Shanghai
Age
15 years to 75 years
People
129 worldwide
Run by
Yunfeng Cheng
See details and how to joinNCT06479317
Phase 2Taking people
TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment Termination
Where
Beijing
Age
18 years to 50 years
People
56
Run by
Peking Union Medical College Hospital
See details and how to joinNCT06478537